omicron hospitalization rate vaccinated by age

J. Med. On March 18, 2022, this report was posted online as an MMWR Early Release. Adults whose vaccination status had not yet been verified using the immunization information system data were considered to have unknown vaccination status and were included in total proportions but not stratified by vaccination status. The outcomes were the infants first positive nasal/throat swab for SARS-CoV-2 by PCR, and the first COVID-19-related hospitalization, occurring during the first 6 months of life and recorded in the electronic health record. Vaccinated patients were older (68 vs. 57 years), and 62% had at least one comorbidity Admission to the ICU was 20%, and the mortality rate at 30 days was 14%. * Data are from a weighted sample of hospitalized nonpregnant adults with completed medical record abstractions and a discharge disposition. Author's reply, Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India, Centers for Disease Control and Prevention, MRC Biostatistics Unit COVID-19 Working Group, Cases, hospital admissions, and hospital attendances in those with delta and omicron SARS-CoV-2 variants, between Nov 29, 2021, and Jan 9, 2022, Risk of hospitalisation and mortality for COVID-19 cases with omicron compared with delta, overall and by age group, Estimated HRs for vaccination categories, secondary analysis. A previous study conducted before the Omicron-predominant period that showed increased risk for COVID-19associated hospitalization among certain racial and ethnic groups, including Black adults, and suggested the increased hospitalization rates were likely multifactorial and could include increased prevalence of underlying medical conditions, increased community-level exposure to and incidence of COVID-19, and poor access to health care in these groups (7). adjudicated chart reviews. You will be subject to the destination website's privacy policy when you follow the link. After the emergence of the Omicron variant, the rate of COVID-19 hospitalizations in the United States was 10.5 times higher in unvaccinated adults and 2.5 times higher in those who were vaccinated but received no booster than in booster recipients, according to a new study. It is possible that this practice may have led to some misclassification of the outcome, and we were unable to assess whether this misclassification was differential between vaccinated and unvaccinated mothers. J. Med. J. Med. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Omicron vaccine effectiveness estimates for 7 to 59 days, 60 to 119 days, and 240 days or more after the second dose are not presented owing to imprecision in the estimates and wide 95% CIs (ie, 100 percentage points). Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers compared with infants of unvaccinated mothers (21/100,000 person-years vs. 100/100,000 person-years). Top editors give you the stories you want delivered right to your inbox each weekday. However, data currently available on the persistence of immunity after vaccination on the one hand and the emergence of viral variants with reduced sensibility to vaccine immunity on the other, raise the need to administer boosters to maintain the protection and to compare . Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 yearsVISION Network, 10 states, April 2021-January 2022. But those countries have high vaccination rates, and there, too, Omicron has spread most quickly among younger adults. Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection. In January 2022, unvaccinated adults and those vaccinated with a primary series, but no booster or additional dose, were 12 and three times as likely to be hospitalized, respectively, as were adults who received booster or additional doses. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in 1CDC COVID-19 Emergency Response Team; 2General Dynamics Information Technology, Atlanta, Georgia; 3California Emerging Infections Program, Oakland, California; 4Career Epidemiology Field Officer Program, CDC; 5Colorado Department of Public Health & Environment; 6Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut; 7Emory University School of Medicine, Atlanta, Georgia; 8Georgia Emerging Infections Program, Georgia Department of Public Health; 9Atlanta Veterans Affairs Medical Center, Atlanta, Georgia; 10Iowa Department of Public Health; 11Michigan Department of Health and Human Services; 12Minnesota Department of Health; 13New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico; 14New York State Department of Health; 15University of Rochester School of Medicine and Dentistry, Rochester, New York; 16Ohio Department of Health; 17Public Health Division, Oregon Health Authority; 18Vanderbilt University Medical Center, Nashville, Tennessee; 19Utah Department of Health. A recent study found that the mean titer of maternally derived antibodies in infants of vaccinated mothers were higher at age 2 months compared with antibody titers at age 6 months23. Introduction: A rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines. . No other exclusion criteria were applied. J. Med. Age was the most important risk factor for COVID-19 death (eg, HR, 31.3 for an 80-year-old vs a 50-year-old). Background: Risk stratification models have been developed to identify patients that are at a higher risk of COVID-19 infection and severe illness. COVID-19 vaccination coverage among pregnant women during pregnancyEight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. If SARS-CoV-2 test date was missing, hospitalization admission date was used. Zerbo, O. et al. Clinical trends among U.S. adults hospitalized with COVID-19, March to December 2020: a cross-sectional study. However, these Omicron impacts have been mostly observed in countries with high vaccination rates in the Region: the comparatively lower rate of hospitalizations and deaths so far is in large part thanks to vaccination, particularly of vulnerable groups. J. Med. All adults should stay up to date (1) with COVID-19 vaccination to reduce their risk for COVID-19associated hospitalization. During the Omicron dominant period, maternal vaccination with at least two doses reduced the infants risk of testing SARS-CoV-2 positive by 43% (95% CI: 4, 69) during the first 2 months of life, 36% (95% CI:11, 55) during the first 4 months of life, and 41% (95% CI: 25, 53) during the first 6 months of life (Supplemental Table2). Vaccine 31, 21652168 (2013). Google Scholar. Suggested citation for this article: Taylor CA, Whitaker M, Anglin O, et al. Chi-square tests were used to compare differences between the Delta- and Omicron-predominant periods; p-values <0.05 were considered statistically significant. After the emergence of the Omicron variant, the rate of COVID-19 hospitalizations in the United States was 10.5 times higher in unvaccinated adults and 2.5 times higher in those who were vaccinated but received no booster than in booster recipients, according to a new study. Cite this article. And in a second large study during the Omicron period, older people, men, and residents of nursing homes or in low-income areas were most at risk for post-booster COVID-19 death in England, but the risk was very low. Relative to unvaccinated hospitalized patients, hospitalized vaccinees were more likely to be older (median age, 70 vs 58 years) and to have at least three underlying conditions (77.8% vs 51.6%). Halasa, N. B. et al. "The subpopulations with the highest risk should be considered a priority for COVID-19 therapeutics and further booster doses.". During the Omicron dominant period, receipt of 2 doses during pregnancy reduced the risk of the infant testing SARS-CoV-2 positive by 21% (95% CI: 21, 48) during the first 2 months of life, 14% (95% CI: 8, 32) during the first 4 months of life, and 13% (95% CI: 3, 26) during the first 6 months of life (Table2). Over the entire study period, the crude rate of hospitalization with a SARS-CoV-2 positive test was lower during the first 6 months of life among infants whose mothers received at least two doses of mRNA COVID-19 vaccines during pregnancy compared with infants whose mothers were unvaccinated during pregnancy (21/100,000 PY vs. 100/100,000 PY). Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. Most hospitalized children were unvaccinated, and nearly one in three were Black. Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Additional COVID-NET methods for determining vaccination status have been described previously. Mortal. During the Omicron-predominant period, overall weekly adult hospitalization rates peaked at 38.4 per 100,000, exceeding the previous peak on January 9, 2021 (26.1) and the peak rate during the Delta-predominant period (15.5) (Figure 1). However, in contrast with the Norwegian study which reported that infants of mothers who were vaccinated had a 33% decreased risk of testing positive during the first 4 months of life during the Omicron period17, our study found a 13% reduced risk that was not statistically significant. Our additional supplemental analysis suggests that pregnant persons who received at least one vaccine dose before pregnancy should complete their vaccination series during pregnancy to provide protection to their children during the first 6 months of life. Adults who received booster doses were classified as those who completed the primary series and received an additional or booster dose on or after August 13, 2021, at any time after completion of the primary series, and 14 days before a positive test result for SARS-CoV-2, because COVID-19associated hospitalizations are a lagging indicator and time passed after receipt of a booster dose has been shown to be associated with reduced rates of COVID-19 infection (https://www.nejm.org/doi/full/10.1056/NEJMoa2114255). Adults with no documented receipt of any COVID-19 vaccine dose before the test date were considered unvaccinated. GD declares that his employer UK Health Security Agency (previously operating as Public Health England) received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. Receipt of one dose especially during the third trimester was also associated with a reduced risk of infants testing positive for SARS-CoV-2 during the first 6 months of life during the Delta dominant period.